Latest Conference Articles

Novel Bispecific Monoclonal Antibody Demonstrates Preclinical Promise Against STEAP1 Target in mCRPC

Novel Bispecific Monoclonal Antibody Demonstrates Preclinical Promise Against STEAP1 Target in mCRPC

October 23rd 2020, 9:45pm

Prostate Cancer Foundation Scientific Retreat

In a presentation during the 27th Annual Prostate Cancer Foundation Scientific Retreat, W. Kevin Kelly, DO, explained the potential of this novel agent and its development progress.

AR/AKT Combination Bests AR Blockade in mCRPC with PTEN Loss

AR/AKT Combination Bests AR Blockade in mCRPC with PTEN Loss

October 23rd 2020, 8:15pm

Prostate Cancer Foundation Scientific Retreat

The combination of ipatasertib and abiraterone acetate achieved a significantly superior radiographic progression-free survival and demonstrated anti-tumor activity compared with placebo and abiraterone in patients with metastatic castration resistant prostate cancer with PTEN loss, according to results from the phase 3 IPATential150 clinical trial.

PSMA-Targeted Therapies in Clinical Development Show Promise for Prostate Cancer

PSMA-Targeted Therapies in Clinical Development Show Promise for Prostate Cancer

October 23rd 2020, 5:30pm

Prostate Cancer Foundation Scientific Retreat

Naomi Haas, MD, discusses several areas of interest for the treatment of patients with prostate cancer that are utilizing PSMA, including bispecific T-cell engager antibodies, chimeric antigen receptor T cells, and the lutetium studies.

BXCL701 Split Dosing Improves Tolerability in Metastatic Castration-Resistant Prostate Cancer

BXCL701 Split Dosing Improves Tolerability in Metastatic Castration-Resistant Prostate Cancer

October 22nd 2020, 6:15pm

Prostate Cancer Foundation Scientific Retreat

Split-dosing of BXCL701 at 0.6 mg per day is a supported dosing strategy for the agent in combination with pembrolizumab as treatment of patients with metastatic castration-resistant prostate cancer, according to phase 1b/2 study results.

PLK1 Inhibitor, Abiraterone Combo Shows Preliminary Efficacy and Safety in mCRPC

PLK1 Inhibitor, Abiraterone Combo Shows Preliminary Efficacy and Safety in mCRPC

October 22nd 2020, 6:00pm

Prostate Cancer Foundation Scientific Retreat

In a phase 2 trial, onvansertib, a polo-like kinase 1 inhibitor, combined with abiraterone acetate in patients with metastatic castration-resistant prostate cancer who have early abiraterone resistance, demonstrated a decent safety profile across 3 dosing schedules and efficacy in the evaluable arms.

Optimal Strategies for Treatment of Multiple Myeloma in Newly Diagnosed Patients

Optimal Strategies for Treatment of Multiple Myeloma in Newly Diagnosed Patients

October 11th 2020, 10:15pm

NCCN 2020 Virtual Congress: Hematologic Malignancies

During a presentation at the National Comprehensive Cancer Institute 2020 Virtual Congress: Hematologic Malignancies, Shaji K. Kumar, MD, explained that each case of multiple myeloma requires a long-term strategy that starts with a strong approach in the frontline setting.

Treatment Options Expand Beyond JAK Inhibition for Patients With Myelofibrosis

Treatment Options Expand Beyond JAK Inhibition for Patients With Myelofibrosis

October 11th 2020, 6:30pm

NCCN 2020 Virtual Congress: Hematologic Malignancies

During the National Comprehensive Cancer Network 2020 Virtual Congress: Hematologic Malignancies, Aaron Gerds, MD, MS, reviewed the current treatment landscape for patients with myelofibrosis and what’s to come for the treatment of this patient population as clinical trials continue to advance the field.

Expert Reviews New Diagnostic and Staging Criteria in Multiple Myeloma

Expert Reviews New Diagnostic and Staging Criteria in Multiple Myeloma

October 11th 2020, 3:30pm

NCCN 2020 Virtual Congress: Hematologic Malignancies

In an interview with Targeted Oncology, Jens Hillengass, MD, shared his insights on the latest edition of the diagnostic and staging criteria for multiple myeloma that have become standard now for the management of these patients.

Hot Topics of Discussion in the Management of Multiple Myeloma

Hot Topics of Discussion in the Management of Multiple Myeloma

October 11th 2020, 1:00pm

NCCN 2020 Virtual Congress: Hematologic Malignancies

Jens Hillengass, MD, discusses the key takeaways from his presentation at the 2020 National Comprehensive Cancer Network Virtual Congress: Hematologic Malignancies, in which he shared his insights on the diagnostic and staging criteria in multiple myeloma.

Mounting Data for Small Molecule Therapies in CLL Push Chemoimmunotherapy Further From the Frontline

Mounting Data for Small Molecule Therapies in CLL Push Chemoimmunotherapy Further From the Frontline

October 10th 2020, 10:15pm

NCCN 2020 Virtual Congress: Hematologic Malignancies

The growing use of minimal residual disease as a prognostic marker of progression-free survival and overall survival suggests that it might aid in clinical decision-making.